JF
CLDX icon

Jump Financial’s Celldex Therapeutics CLDX Stock Holding History

Jump Financial’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33M Buy
116,293
+107,473
+1,219% +$3.47M 0.03% 577
2026
Q1 		$280K Sell
8,820
-136,344
-94% -$3.72M ﹤0.01% 1515
2025
Q4 		$3.94M Buy
145,164
+131,021
+926% +$3.45M 0.05% 431
2025
Q3 		$366K Sell
14,143
-15,360
-52% -$356K ﹤0.01% 1425
2025
Q2 		$600K Buy
29,503
+10,255
+53% +$200K 0.01% 1166
2025
Q1 		$349K Buy
19,248
+2,735
+17% +$61.1K ﹤0.01% 1236
2024
Q4 		$417K Buy
+16,513
New +$449K 0.01% 1165
2023
Q1 		– Sell
-21,253
Closed -$947K – 1647
2022
Q4 		$947K Buy
+21,253
New +$759K 0.05% 506
2021
Q3 		– Sell
-51,400
Closed -$1.72M – 1142
2021
Q2 		$1.72M Buy
+51,400
New +$1.41M 0.17% 143
2021
Q1 		– Sell
-13,100
Closed -$229K – 982
2020
Q4 		$229K Buy
+13,100
New +$236K 0.04% 721

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jump Financial's CLDX Position: Q2 2026 in Review

Jump Financial increased its Celldex Therapeutics (CLDX) stake by 1,219% in Q2 2026, buying an estimated $3.47M and bringing the position to 116,293 shares worth $4.33M. The position accounts for 0.03% of the portfolio, ranked #577.

Jump Financial first reported a position in CLDX in Q4 2020 and has held it in 10 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Jump Financial held 116,293 shares of Celldex Therapeutics worth $4.33M as of Q2 2026.
  • Jump Financial bought 107,473 Celldex Therapeutics shares in Q2 2026, an estimated $3.47M.
  • Celldex Therapeutics made up 0.03% of Jump Financial's portfolio in Q2 2026, its #577 holding.
  • Jump Financial first reported a position in Celldex Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Jump Financial's 13F filing for Q2 2026, filed 13 Aug 2026.